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Abstract
Objectives: Early detection and treatment of an oral squamous cell carcinoma (OSCC) is critical because of its 
rapid growth, frequent lymph-node metastasis, and poor prognosis. However, no clinically-valuable methods of 
early diagnosis exist, and genetic analysis of OSCCs has yielded no biomarkers.
Study Design: We investigated the expression of genes associated with inflammation in OSCCs via a quantitative 
reverse transcriptase polymerase chain reaction (qRT-PCR) analysis of microarray data. Tumor and normal tissues 
from five patients with an OSCC were used for microarray analysis. Differentially-expressed genes, identified us-
ing permutation, local pooled error (LPE), t-tests, and significance analysis of microarrays (SAM), were selected 
as candidate genetic markers.
Results: Two groups corresponding to tissue identity were evident, implying that their differentially-expressed 
genes represented biological differences between tissues. Fifteen genes were identified using the Student’s paired 
t-test (p<0.05) and the SAM, with a false discovery rate of less than 0.02. Based on gene expression, these 15 
genes can be used to classify an OSCC. A genetic analysis of functional networks and ontologies, validated by 
using a qRT-PCR analysis of the tissue samples, identified four genes, ADAM15, CDC7, IL12RB2 and TNFRSF8, 
that demonstrated excellent concordance with the microarray data.
Conclusions: Our study demonstrated that four genes (ADAM15, CDC7, IL12RB2 and TNFRSF8) had potential 
as novel biomarkers for the diagnosis and the treatment of an OSCC.
Key words: Biomarker, microarray, quantitative reverse transcription polymerase chain reaction, oral squamous 
cell carcinoma, gene expression profiling.
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Introduction
An oral squamous cell carcinoma (OSCC), a subtype of 
head and neck squamous cell carcinomas, is the sixth 
most common malignancy worldwide, accounting for 
3% of all cancers (1,2), and it remains one of the most 
intractable malignancies due to its invasive growth pat-
tern, frequent cervical lymph-node metastasis and high 
recurrence rate (3). Approximately two-thirds of pa-
tients with an OSCC exhibit an advanced stage (Stage 
III or IV) at diagnosis because of its similarity to in-
flammatory disease, its long asymptomatic period and 
its challenging clinical differentiation (4,5). Therefore, 
early detection of an OSCC is critical.  For that purpose, 
screening methods, such as light-based screening or 
brush cytology, have been introduced, but their sensitiv-
ity and specificity are insufficient compared with those 
of scalpel biopsy. Hence, histopathological examination 
is still a cornerstone of diagnosis; however, excluding 
the possibility of misdiagnosis completely is difficult 
due to the inherent vagueness of the histopathological 
characteristics of an OSCC and variations in the pathol-
ogists’ experience.
Recently, mRNA biomarkers for an OSCC in serum or 
tissue have become new diagnostic and therapeutic tar-
gets because suitable biomarkers can improve the power, 
availability and cost-effectiveness of high-throughput 
screening for genetic alterations. Microarray analysis, 
validated by using the quantitative reverse transcriptase 
polymerase chain reaction (qRT-PCR), has been used 
to identify the genes underlying OSCC pathogenesis, 
which include IL-8 and VEGF (6). Some investigators 
have employed a multiple-gene model of 25 biomark-
ers with 86%-89% accuracy (7). However, no studies 
have established clinically-valuable biomarkers, which 
may be due to a lack of studies with tumor-normal (TN) 
paired matching of patients (8) or to the limited predic-
tive power of microarray-based models to correlate the 
clinical endpoint with gene expression (9).  In this study, 
we investigated the expression of genes associated with 
cancer and inflammation in patients with an OSCC by 
using microarray analysis, which was validated by us-
ing the qRT-PCR. These results were assessed by bio-
informatics verification. With this approach, we tried to 
identify novel biomarkers for OSCC.
Material and Methods
1.1. Patients
TN-paired tissues from five OSCC patients were used 
for the microarray analysis. Subsequently, tissues from 
17 OSCC patients (TN-paired) were used for the qRT-
PCR analysis. Fresh tissue samples were collected after 
obtaining written informed consent from 34 consecu-
tive patients undergoing therapeutic surgical resection 
for an OSCC between 1 June 2011 and 28 June 2012. 
The patients’ characteristics are outlined in table 1. 
After excision, tissues were preserved immediately in 
RNAlater® solution (Invitrogen, USA) until use and 
were transferred to the laboratory on ice. This trial was 
approved by the Institutional Review Board at Seoul 
National University Dental Hospital and was conducted 
in full accordance with the Declaration of Helsinki.
1.2. RNA extraction and cDNA synthesis
RNAlater® was pipetted off the pellet, and the pellet was 
then washed with ice-cold phosphate-buffered saline, 
which was removed after centrifugation. Total RNA was 
extracted from the tissue samples by using the RNeasy® 
Mini Kit (Qiagen, Germany) according to the manufac-
turer’s instructions. To quantify and analyze the integrity 
of RNA, we used 2100 Bioanalyzer® (Agilent Technolo-
gies, USA). We reversely transcribed 10 μg of total RNA 
in the presence of an oligo (dT) T7 primer (iScript™ Se-
lect cDNA Synthesis Kit; Bio-Rad Laboratories, USA). 
cDNA was used for in-vitro transcription amplification 
in the presence of biotinylated nucleotides.
1.3. Microarray analysis
Gene expression was analyzed using the Affymetrix 
preparation protocol before hybridization to a Gene-
Chip® 1.1 human genome microarray (Affymetrix, 
USA). Quality control of the arrays was achieved 
through analysis of the 5’:3’ ratios (range: 0.40-0.79), 
the percentage present (range: 37-47%), the average 
pair-wise correlation, and the principal component. Af-
fymetrix® Microarray Suite version 5.0 (Affymetrix) 
was used for image processing and data acquisition. 
Gene expression levels and individual exon signal esti-
mates contained in*. CEL files within the GeneChip® 
1.1 platform (Affymetrix) were derived by using the 
robust multi-array average (RMA) algorithm, as imple-
mented by the Expression Console v1.1.1 (Affymetrix). 
The quality of the data was assessed by analyses of the 
mean overall expression and its standard deviation, the 
detectable probe ratios, the control probe’s (housekeep-
ing genes) expression data, and the correlation between 
samples from the same tissue.
1.4. Quantitative reverse transcription polymerase chain 
reaction
Target and housekeeping gene sequences were re-
trieved from the GenBank® database (National 
Center for Biotechnology Information (NCBI), USA), 
and applied primers were manually designed using 
the Primer-BLAST® tool (NCBI). Primer sequences 
are listed in table 2. RNA mixtures were subjected to 
first-strand cDNA synthesis using forward primers. 
The endogenous housekeeping genes, hypoxanthine 
guanine phosphoribosyl transferase (NM_000194.2) 
and β–actin (NM_001101.3), were used for data nor-
malization, and relative quantification was performed 
by using a relative standard curve analysis with a CFX 
Connect™ Real-Time PCR Detection System (Bio-Rad 
Laboratories) and SYBR® Green I (Bio-Rad Labora-
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tories) detection. cDNA (10ng) was dissolved in iQ™ 
SYBR® Green Supermix. The PCR comprised an ini-
tialization cycle (95°C for 3 minutes); 39 cycles of 95°C 
for 10 seconds, 56°C for 10 seconds, 72°C for 20 sec-
onds, and plate reading at 80°C; and a final melting step 
at temperatures ranging from 56 to 95°C at a heating 
rate of 0.5°C/10 seconds, which was performed to create 
melt curves. The qRT-PCR was performed in quadru-
plicate for each cDNA samples, and negative controls 
with no template were included for each primer pair. 
Threshold cycle (Ct) values and target gene expression 
levels were calculated using CFX Manager™ Software 
(Bio-Rad Laboratories). The fold change of target gene 
expression in each treated sample, relative to the con-
Parameter Study (Microarray) Validation (qRT-PCR) 
TN paired 
(n=5) 
Normal
(n=20) 
Tumour
(n=25) 
TN paired 
(n=17) 
Age (yrs)     
 <50 0 (0) 2 (10) 4 (16) 2 (11.8) 
50 5 (100) 18 (90) 21 (84) 15 (88.2) 
Gender     
 Male 4 (80) 10 (50) 12 (48) 9 (52.9) 
 Female 1 (20) 10 (50) 13 (52) 8 (47.1) 
Therapy prior to surgery     
 None 3 (60) 17 (85) 21 (84) 14 (82.4) 
 Yes 2 (40) 3 (15) 4 (16) 3 (17.6) 
Smoking history *     
 Yes 3 (60) 2 (10) 4 (16) 2 (11.8) 
 No 2 (40) 18 (90) 21 (84) 15 (88.2) 
Alcohol history     
 Yes 2 (40) 1 (5) 3 (12) 1 (5.9) 
 No 3 (60) 19 (95) 22 (88) 16 (94.1) 
Histological grading     
 Well-differentiated 2 (40) 12 (60) 16 (64) 11 (64.7) 
 Mod-differentiated 1 (20) 7 (35) 9 (36) 6 (35.3) 
 Poorly-differentiated 0 (0) 0 (0) 0 (0) 0 (0) 
 Unknown 2 (40) 1 (5) 0 (0) 0 (0) 
Clinical stage     
 I/II 1 (20) 4 (20) 6 (24) 3 (17.6) 
 III/IV 4 (80) 16 (80) 19 (76) 14 (82.4) 
Lymph node involvement 
(Pathologic) 
    
 Negative 2 (40) 9 (45) 11 (44) 7 (41.2) 
 Positive 2 (40) 7 (35) 10 (40) 7 (41.2) 
 Unknown 1 (20) 4 (20) 4 (16) 3 (17.6) 
T classification (Pathologic)     
 T1/T2 4 (80) 10 (50) 12 (48) 9 (52.9) 
 T3/T4a 1 (20) 10 (50) 13 (52) 8 (47.1) 
Tumour site     
 Alveolar gum 2 (40) 7 (35) 13 (52) 6 (35.3) 
 Tongue 2 (40) 4 (20) 3 (12) 3 (17.6) 
 Palate 0 (0) 4 (20) 3 (12) 3 (17.6) 
 Other 1 (20) 5 (25) 6 (24) 5 (29.4) 
Recurrence     
 Locoregional recurrence 0 (0) 2 (10) 3 (12) 2 (11.8) 
 Lymph node metastasis 2 (40) 2 (10) 2 (8) 2 (11.8) 
 Distal metastasis 0 (0) 2 (10) 2 (8) 2 (11.8) 
 No recurrence 3 (60) 14 (70) 18 (72) 11 (64.7) 
Table 1. Clinicopathological characteristics of patients in this study and the Qualitative Reverse Transcrip-
tion Polymerase Chain Reaction Validation Group.
TN paired, tumour-normal matching among participants.
The Chi-squared or Fisher’s exact testswere used to compare the Microarray Study and Quantitative Reverse 
Transcription Polymerase Chain Reaction Validation Groups.
* p < 0.05
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trol sample, was derived from the negative Ct value: Ct 
(GAPDH)−Ct (target gene).
1.5. Data analysis and statistics
Differences in the clinical characteristics between the 
Microarray Study and the qRT-PCR Validation groups 
were compared using the Chi-square test. If this method 
was not suitable, a Fisher’s exact test or a linear-by-lin-
ear association test was used.  Differentially expressed 
genes (DEGs), identified by using four statistical tests 
(permutation test, local pooled error (LPE) (10), Stu-
dent’s paired t-test, and significance analysis of micro-
arrays (SAM) (11), were selected as candidates for ge-
netic biomarkers (12), and their normalities were tested 
using the Shapiro-Wilk test (13). After the normality 
had been tested, genes that were normally distributed 
were assessed using the t-test, the SAM and the LPE 
(parametric methods). The genes that were not distrib-
uted normally were assessed using a non-parametric 
permutation test. 
For the multiple-comparison problem, p-values were 
adjusted using the false discovery rate (FDR) correc-
tion. To find candidates, we tried to use FDR values as 
close to 0% as possible, and those for the SAM and the 
permutation test were set to 0%. On the other hand, the 
FDRs for the LPE and the t-test were set to 0.001% and 
0.02%, respectively, because no significant candidate 
genes were found when their FDRs were set to 0%. 
A discriminant analysis was used to find correlations 
between the candidate gene expressions and clinical 
parameters such as tissue heterogeneity, site specifi-
city, and stage differences. From receiver-operating-
characteristic (ROC) curves, the area under the curve 
(AUC), the sensitivity, the specificity, and the predictive 
value of each candidate gene were calculated using the 
Youden index. All statistical analyses, except the analy-
ses of the ROC curves, which were done using Med-
Calc® Statistical Software version 12.7.8 (MedCalc® 
Software bvba, Ostend, Belgium), were conducted us-
ing R Statistical Software version 2.15.0 (from http://
www.r-project.org/) and IBM SPSS® version 20 (IBM 
Co., Armonk, NY, USA).  
Results 
2.6.  Patient characteristics
Thirty-three patients with an OSCC, 17 men (51.5%) 
and 16 women (48.5%), were included in this study (Ta-
ble 1). We analyzed the DEGs in five patients by using 
microarray analyses to compare primary TN-paired tis-
sue samples. Tumor (n=20) and normal tissues (n=25) 
from another 28 patients were used for the qRT-PCR 
validation. Of those 28 participants, 17 were assayed for 
expression via the qRT-PCR of primary tumor samples 
and matched normal mucosa. No statistically signifi-
cant differences in clinical characteristics between the 
Microarray Study and the qRT-PCR Validation groups 
were observed (p > 0.05). 
2.7.  Statistical analysis of candidate genes identified by 
using a microarray analysis 
A t-test was performed to detect the DEGs. However, 
the test assumes that all data follow a normal distribu-
tion. Therefore, a non-parametric permutation test was 
also conducted to identify DEGs, and its results were 
evaluated using the SAM and the LPE test. The LPE 
test was proposed to overcome the limitation caused by 
the different error variances arising from the diverse 
biological conditions via local error estimation within 
 Gene Symbol RefSeq_ID Sequences (5’->3’) 
Housekeeping genes 
?-actin NM_001101.3 Forward  AGA GCT ACG AGC TGC CTG AC 
Reverse  GGA TGC CAC AGG ACT CCA 
HPRT NM_000194.2 Forward  ATC CAT TGG AGG GCA AGT C 
Reverse  GAG CTT TTT AAC TGC AGC AAC TT 
Target genes ADAM15 NR_040773.1 Forward  CAG GAG ACA GCT CCC AGT GT 
Reverse  CAA AAG CAT TTC CCC GAG TA 
 
CDC7 NM_003503.3 Forward  GCT CAG CAG GAA AGG TGT TC 
Reverse  AGC TTT TGT GGT GGA CTG CT 
 
IL12RB2 NM_001258216.1 Forward  ACT GGA GCC TCA GCA CAT CT 
Reverse  AGC CTC ACC ACT CAG AGC AT 
 
TNFRSF8 NM_001243.3 Forward  GCT CAG ATG TTT TGG GGA AA 
Reverse  AGA CAC CCA CTC CAT CCT TG 
Table 2. Primer pairs for reverse transcription polymerase chain reaction validation of candidate biomarker gene expression levels.
HPRT, hypoxanthine phosphoribosyltransferase
ADAM15, a disintegrin and metalloproteinase metallopeptidase domain 15
CDC7, cell division cycle 7 homolog
IL12RB2, interleukin 12 receptor, beta 2
TNFRSF8, tumour necrosis factor receptor superfamily, member 8
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quantiles and non-parametric smoothing (10). The SAM 
scores gene expression relative to the deviation of re-
peated measurements in order to identify genes with 
high scores above an adjustable threshold, and for those 
identified genes, the FDRs and the percentage of identi-
fication by chance were estimated (Fig. 1) (11).
Of the 33,297 genes on the microarray, the numbers of 
genes with significance, which were assessed with the t-
Fig. 1. Hierarchical clustering of microarray gene expression data. The dendogram at the bottom lists all samples arrayed and measures their 
degree of relatedness in terms of gene expression. All samples were coded with numbers, as shown in table 1. The colored bar beneath the sample 
identifiers marks samples from patients, where the Normal Group of patients with oral squamous cell carcinoma are in red and those from the 
Tumour Group are in blue (A). Genes identified by all four statistical tests (the permutation, LPE and t-tests and SAM) were selected as candidate 
genetic markers. The 15 genes passed Student’s paired t-test and SAM analysis (B).
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test, the SAM and the LPE (parametric methods), were 
779, 349 and 200, respectively. None of these genes 
showed statistical significance in all 3 methods, but 15 
genes did in both the t-test and the SAM. However, no 
genes showed significance in the non-parametric per-
mutation test. The 15 genes showed differential expres-
sion patterns; 10 genes were predominantly upregulated 
and five were predominantly downregulated (Table 3). 
Four statistical tests (the permutation test, the LPE, the 
Student’s paired t-test, and the SAM) were used to iden-
tify the DEGs, and common DEGs identified by using 
the t-test and the SAM were selected as biomarker can-
didates.
Fifteen genes passed the Student’s paired t-test (p < 
Gene 
Symbol 
Gene name 
/Accession No. Role 
Disease
relationship 
 
C1orf93 
(FAM213B) 
 
family with sequence similarity 213, 
member B(NM 001195736.1) 
 
Catalyzes the reduction of 
prostaglandin H2 to prostaglandin F2? 
Unknown 
ARHGEF16 Rho guanine nucleotide exchange factor 16(NM 014448.3) 
Role in chemotactic cell migration and 
mediate activation of CDC42 by 
HPV16 
Unknown(Oliver et al, 
2011) 
ZBTB48 zinc finger and BTB domain containing 48(NM 005341.2) 
Binds to and regulates the J and/or S 
elements in MHC II promoter Unknown 
TNFRSF8 
tumour necrosis factor receptor 
superfamily, member 8 
(NM 001243.3) 
Positive regulator of apoptosis. Limit 
the proliferative potential of 
autoreactive CD8 effector T cells and 
protect the body against the 
autoimmunity. 
Hodgkin disease, anaplstic 
large cell 
lymphoma(Durkop et al, 
1992) 
UTP11L 
UTP11-like, U3 small 
nucleolarribonucleoprotein(NM 
016037.3) 
Involved in nucleolar processing of pre-
18S ribosomal RNA Unknown 
PLK3 polo-like kinase 3 (NM 004073.2) 
Play a role in regulation of cell cycle 
progression and tumourigenesis 
Cancer, tumour (Li et al, 
1996) 
IL12RB2 interleukin 12 receptor, beta 2 (NM 001258214.1) 
Role in the differentiation of T helper 1 
cell and promote the proliferation of T 
cells as well as natural killer cells. 
Allergic asthma, Burkitt 
lymphoma, autoimmunity 
(Bassuny etal, 2003) 
WDR63 WD repeat domain 63 (NM 145172.3) Unknown Unknown 
CDC7 cell division cycle 7 homolog (NM 001134419.1) 
Phosphorylate critical substrates that 
regulate the G1/S phase transition 
and/or DNA replication 
Tumour, cancer, ataxia 
telangiectasia(Tenca et al, 
2007) 
KCNC4 
potassium voltage-gated channel, 
Shaw-related subfamily, member 
(NM 001039574.2) 
Mediates the voltage-dependent 
potassium ion permeability of excitable 
membranes 
Cancer, head and neck 
tumour (Menendez et al, 
2010) 
DCLRE1B DNA cross-link repair 1B (NM 022836.3) 
Role in telomere maintenance and 
protection during S-phase 
Hoyeraal-
Hreidarssonsyndrome(Lenai
n et al, 2006) 
LCE1D Late cornified envelope protein 1D (NM 178352.2) 
Precursors of the cornified envelope of 
the stratum corneum 
Eczema(Marenholz et al, 
2011) 
ATP8B2 ATPase, class I, type 8B, member 2 (NM 001005855.1) 
Operate at the plasma membrane and 
essential for endoplasmic reticulum exit 
Unknown(Harris,Arias, 
2003) 
ADAM15 ADAM metallopeptidase domain 15 (NM 001261464.1) 
Role in cell-cell interaction, cell 
migration, signal transduction, wound 
healing and pathological 
neovascularization. 
Osteoarthritis, cancer, 
metastasis(Zhong et al, 
2008) 
KLHDC7A kelch domain containing protein 7A (NM 152375.2) Unknown 
Diabetic retinopathy, 
autism(Kuwano et al, 2011) 
Table 3. Fifteen candidate genes whose expression differed between normal and tumour tissue in oral squamous cell carcinoma as indi-
cated by microarray analysis (tumour–normal-paired; n = 5).
CDC42, cell division control protein 42 
HPV16, human papillomavirus 16
MHC, major histocompatibility complex
Note: GeneChip® 1.1 human genome microarrays (Affymetrix, Inc., Santa Clara, CA, USA) were used to identify the difference in RNA 
expression patterns in tissues from five cancer patients and five matched normal subjects
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0.05) and the SAM analysis with an FDR of <0.02. To 
test the ability of this signature gene set to classify the 
OSCC and the Normal groups, we performed an aver-
age linkage hierarchical clustering analysis. Based on 
gene expression, this 15-gene set has classification pow-
er for an OSCC (Fig. 2). In this set, upregulated genes 
were FAM213B, ARHGEF16, ZBTB48, DCLRE1B, 
LCE1D, KLHDC7A, TNFRSF8, IL12RB2, CDC7 and 
ADAM15 while UTP11L, PLK3, WDR63, KCNC4 and 
ATP8B2 were downregulated.
2.8. Analysis of the literature related to candidate 
genes
An ontological analysis revealed the function and the 
disease association of each gene, identifying genes 
involved in inflammation or immunity (FAM123B, 
ZBTB48, TNFRSF8 and IL12RB2), intercellular sig-
nalling and movement (ARGHEF16, KCNC4 and AD-
AM15), transcription (UTP11L and ATP8B2), cell divi-
sion (PLK3, CDC7 and DCLRE1B) and keratinization 
(LCE1D) (14-24). After a literature review, we excluded 
well-known genes associated with carcinogenesis, such 
as PLK 3 and KCNC 4, and unidentified genes, includ-
ing WDR63 and KLHDC7A. Among the remaining 
genes, upregulated ones were chosen as candidates. Of 
them, ARHGEF16 and DCLRE1B were excluded due 
to their unknown correlation with the tumor. Finally, 
IL12RB2, TNFRSF8, ADAM15 and CDC7 remained. 
According to previous research, these 4 genes are 
known to be related to inflammation, carcinogenesis or 
metastasis (14,16,18,19).
2.9. Quantitative reverse transcriptase polymerase chain 
reaction validation of gene expression
Expressions of the four candidate genes (ADAM15, 
CDC7, IL12RB2 and TNFRSF8) were assayed by using 
the qRT-PCR in 28 OSCC samples to correlate microar-
ray data with the qRT-PCR data and to explore potential 
biomarker expression (Fig. 3). Relative expression lev-
els of the four genes were obtained by normalization to 
Fig. 2. Differential expression of 15 genes selected by microarray in oral squamous cell carcinoma and normal tissue. Five genes were down-
regulated, while the other 10 were upregulated. The full line corresponds to the median value for each group.
Med Oral Patol Oral Cir Bucal. 2015 Mar 1;20 (2):e167-79.                                                                                                                                                Biomarker for oral squamous cell carcinoma
e174
housekeeping gene expression levels. The qRT-PCR ex-
pression values for the four candidate genes, whose ex-
pression levels were higher in tumor tissues compared 
with normal tissues, were used for correlation analyses 
using the 2-ΔΔCt method with the Student’s t-test. In 
the tumor group, statistically-significant high mRNA 
expression levels of ADAM15 and CDC7 were con-
sistently detected by using the qRT-PCR (p<0.001 and 
p<0.001, respectively), thus showing excellent agree-
ment with the microarray data. A higher expression in 
the tumor relative to normal tissue was particularly evi-
dent for CDC7 in its increased 2-ΔΔCt value.
We also measured the mRNA expressions of the select-
ed genes in 17 TN-paired tissue samples by using the 
qRT-PCR. The normalized expression was calculated 
by using the 2-ΔΔCt method, as previously described, 
to compare normal and tumor tissues. ADAM15 ex-
pression was significantly increased in tumor tissue 
(p<0.001) by an average of 2.7-fold compared with 
normal tissue (Fig. 4). Consistent with these findings, 
upregulation of CDC7 was evident in tumor tissue (p 
< 0.05). Furthermore, the candidate genes were overex-
pressed regardless of variability in the degree of expres-
sion between samples in the TN-paired group.
2.10. Evaluation of the diagnostic validity of candidate 
genes
The relationships between the clinical parameters and 
the candidate genes are summarized in table 4. Clas-
sification of the primary site by using all four candi-
date genes as signatures resulted in higher accuracy 
(64.7%) than using the ADAM15, CDC7, IL12RB2 and 
TNFRSF8 genes by themselves (35.3%, 47.1%, 23.5% 
and 41.2%, respectively). Similar tendencies were also 
observed regarding tissue heterogeneity and staging. 
These results imply that a combination of multiple can-
didate genes has a discriminatory power that is superior 
to that achieved by using each candidate gene alone.
ROC plots are presented in fig. 5, and their diagnostic 
indices are shown in table 5. The AUCs of ADAM15, 
CDC7, IL12RB2 and TNFRSF8 were 0.699, 0.645, 
0.561 and 0.602, respectively. ADAM15 alone, howev-
er, showed statistical significance (p < 0.05). Similarly, 
the odds ratio of ADAM15 (7.271; p = 0.029) and CDC7 
(26.794; p = 0.046) were statistically significant.
Fig. 3. Quantitative reverse transcription polymerase chain reaction validation of microarray gene expression data from 
tested individuals from the Tumour Group. The quantitative reverse transcription polymerase chain reaction tests were per-
formed with primer sets specific to ADAM15, CDC7, IL12RB2 and TNFRSF8 in 25 patients with oral squamous cell carci-
noma and 20 normal matching samples. p-values (Student’s t-test) are presented. (*P < 0.05; **P < 0.01; ***P < 0.001)
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Fig, 4. Bar chart representation of the mRNA expression of selected genes in tumour and normal patient-matched 
specimens (tumour–normal-paired). Normalised expression was determined by 2-ΔΔCt, by comparing threshold cycle 
values of ADAM15 with β-actin. Overexpression of all genes in tumour tissues is clearly demonstrated. Number of 
cases analysed and corresponding p-values (paired t-test) are provided. (*P < 0.05; **P < 0.01; ***P < 0.001)
ADAM15 CDC7 IL12RB2 TNFRSF8 
Signature of 
4 candidate 
genes
Variables 
Primary site 
Eigen value 0.186 0.232 0.125 0.302 0.658 
Wilks’ Lambda 
0.843
(p=0.512) 
0.812
(p=0.421) 
0.889
(p=0.662) 
0.768
(p=0.312) 
0.450
(p=0.654) 
Accuracy of 
classification 35.3 % 47.1 % 23.5 % 41.2 % 64.7 % 
Eigen value 0.004 0.025 0.000 0.078 0.277 
Wilks’ Lambda 
0.996
(p=0.808) 
0.976
(p=0.550) 
1.000
(p=0.968) 
0.928
(p=0.297) 
0.783
(p=0.529) 
Accuracy of 
classification 35.3 % 47.1 % 47.1 % 58.8 % 76.5 % 
Stage
Eigen value 0.073 0.114 0.120 0.000 0.111 
Wilks’ Lambda 
0.932
(p=0.313) 
0.898
(p=0.212) 
0.893
(p=0.199) 
1.000
(p=0.986) 
0.900
(p=0.849) 
Accuracy of 
classification 52.9 % 47.1 % 70.6 % 35.3 % 58.8 % 
Table 4. The correlation between the clinical parameters and the candidate genes determined by the discriminant analysis.
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Fig. 5. Receiver operating characteristic (ROC) curve for comparing diagnostic validity of the candidate genes. The area under 
the curve (AUC) of ADAM15, CDC7, IL12RB2 and TNFRSF8 were 0.699, 0.645, 0.561 and 0.602, respectively. Among them, 
only ADAM5 showed statistical significance (p < 0.05).
 ADAM15 CDC7 IL12RB2 TNFRSF8 
        ROC curve 
 Sensitivity 52.9 % 52.9 % 35.3 % 35.3 % 
 Specificity 82.4 % 82.4 % 94.1 % 88.2 % 
 Youden index 0.3529 0.3529 0.2941 0.2353 
 AUCa (95% CIb)
0.699 (0.518 
- 0.844) 
0.645 (0.463 
- 0.801) 
0.561 (0.380 
- 0.730) 
0.602 (0.420 
- 0.765) 
 PPVc 75.0 % 75.0 % 85.7 % 75.0 % 
 NPVd 63.6 % 63.6 % 59.3 % 57.7 % 
z 2.189 1.483 0.573 1.014 
p 0.0286* 0.1380 0.5663 0.3104 
        Logistic regression analysis 
 ORe 7.271 26.794 0.001 0.000 
p 0.029* 0.046* 0.980 0.058 
Table 5. The diagnostic validity of the candidate genes for OSCC determined by ROC curves 
and logistic regression analysis.
a AUC : area under the curve calculated
b CI : confidence interval
c PPV : positive predictive value
d NPV : negative predictive value
e OR : odds ratio
* p < 0.05
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Discussion
The five-year survival rate of patients with an OSCC 
has remained about 50% for several decades. This is 
one of the worst prognoses of all cancers and is directly 
related to the advanced stage at diagnosis (25). Local 
recurrence and distant metastasis may develop despite 
an apparently complete excision and histopathologically 
tumor-free margins, supporting the theory of field can-
cerization (26). Novel biomarkers could allow a more 
sensitive and accurate surgical margin to be deter-
mined. However, genome research has been hindered 
by individual and ethnic differences (27).
Although the sample size of the Microarray Study 
group (n = 5) seems too small, we tried to ensure ac-
curate results in three ways: (1) several statistical analy-
ses (the permutation test, the LPE and the SAM), which 
can identify significant DEGs with a small number of 
microarrays, were applied (10), (2) genes carefully se-
lected by using these statistical tools were validated via 
the qRT-PCR with sufficient samples, and (3) as shown 
in table 1, patients’ clinicopathological characteristics 
were evenly distributed in both the Microarray Study 
and the qRT-PCR Validation groups. In spite of a gen-
eral consensus that smoking history is a major contrib-
utor to carcinogenesis (28), gene expression between 
smoking and non-smoking subjects did not differ in this 
study. Further, Méndez et al. observed no statistically-
significant differences in gene expression between pa-
tients with different histopathologic stages when using 
oligonucleotide arrays (29). Thus, the effect of smoking 
history and histopathological type on our results can be 
expected to be minimal. 
To date, many studies have attempted to identify novel 
biomarkers for an OSCC (3,6,30). However, they were 
not generally accepted for the following reasons: First, 
candidate biomarkers yielded by the microarray analy-
sis were usually identified based on fold changes (30), 
but these can often be misleading, as different error 
variances exist under different biological conditions 
and in different microarray expression intensity ranges 
(10). Second, most previous studies mainly focused on 
well-known genes, such as matrix metalloproteinases 
(MMPs), p53 and VEGF (6,8). Such an approach could 
result in a bias against unknown genes. In this study, we 
tried to overcome possible bias by using a microarray 
analysis (a relatively unbiased high-throughput method) 
and to reduce the statistical error by using four kinds of 
biostatistics verification.
From our results, 15 genes were initially screened (Table 
3). As previously mentioned, genes with unknown func-
tions were excluded, and tumor-related ones (ARHGEF16, 
DCLRE1B, TNFRSF8, PLK3, IL12RB2, CDC7, KCNC4 
and ADAM15) were selected. After that, upregulated 
genes (ARHGEF16, DCLRE1B, TNFRSF8, IL12RB2, 
CDC7 and ADAM15) were selected according to hypoth-
esis that upregulated biomarkers are more valuable be-
cause their overexpression will increase the sensitivity of 
diagnosis (31). Among them, 4 genes (ADAM15, CDC7, 
IL12RB2 and TNFRSF8) were selected for further evalua-
tion because of their involvement in malignancy.
ADAM15 is the only member of the disintegrin and 
metalloproteinase (ADAM) family and is involved 
in T-cell-mediated immune responses and pathologic 
neovascularization (32). It is upregulated in breast, 
stomach, lung, pancreas, and prostate cancer and in 
metastatic progression (33). Conversely, its tumor sup-
pression in melanomas and colon carcinomas was also 
proposed (34,35). This inconsistency might result from 
the complexity of the ADAM15-related signal transduc-
tion pathways. In this study, ADAM15 was significantly 
upregulated in patients with an OSCC.
CDC7, a serine threonine kinase, is a core component 
of the initiation machinery of DNA replication, and 
its inhibition in cancer cells induces p53-independent 
apoptosis (36). Clinically, in many kinds of cancers, 
CDC7 upregulation is related to tumor anaplasia, aneu-
ploidy, advanced disease stage and lower relapse-free 
survival (37-39). These results agreed with our data, 
which showed overexpression of CDC7 in patients with 
an OSCC.
IL12RB2 encodes a type-1 transmembrane protein, 
a subunit of the Interleukin 12 (IL-12) receptor com-
plex. IL12RB2 behaves as a tumor suppressor in hu-
man chronic B-cell malignancies, and its silencing is an 
early event in B-cell malignant transformation (27,40). 
Prolonged disease-free survival has also been reported 
to have been found in colorectal cancer patients with 
higher expressions of IL12RB2 (41). However, the cor-
relation between IL12RB2 expression and OSCC devel-
opment is unclear. Considering that interleukin 6 (IL-6) 
and IL-12 functionally antagonize each other and that 
IL-6-induced inflammation promotes carcinogenesis in 
the oral cavity (42,43), IL12RB2 downregulation might 
be involved with an OSCC. However, despite overex-
pression of IL12RB2 in patients with an OSCC in the 
Microarray Analysis group, no significant differences 
of IL12RB2 expression were found in our qRT-PCR 
data.
TNFRSF8 is known to function in apoptosis by activat-
ing the caspase pathway (44) and protecting the body 
against autoimmunity. It is a conventional biomarker of 
hematologic malignancies (45), but its relationship with 
solid tumors is unclear. Only one study reported that 
its overexpression might be associated with improved 
prognosis for patients with a skull base chordoma (46). 
Though TNFRSF8 in patients with an OSCC was up-
regulated in the microarray analysis, qRT-PCR valida-
tion showed no significant differences. Hence, further 
investigation is needed.
Among the four candidates, ADAM15, IL12RB2 and 
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TNFRSF8 are known to be related to inflammation. 
Given that the oral cavity is vulnerable to frequent 
inflammatory stress and that this environment can af-
fect cancer cells, our results support that inflammation 
might be correlated with OSCC development, as report-
ed in some recent studies (6,43).
Table 4 presents the correlation between the candidate 
genes and the clinical parameters (primary site, tissue 
heterogeneity and stage). Although all p values were 
higher than 0.05, the eigenvalues and the accuracies of 
the signatures of the four genes for each parameter were 
generally lower than those of individual genes according 
to the Wilk’s lambda distribution analysis. This result in-
dicates that the classifying power of the four genes com-
bined was superior to that of each gene alone.
As presented in table 5, the sensitivity, specificity and 
predictive values were calculated at the cut-off points ac-
cording to the Youden index.  At the cut-off points, the 
value of [sensitivity + specificity - 1] is a maximum (47). 
The Youden index is widely used to determine the diag-
nostic threshold, and it is regarded as the most appropri-
ate method of combining biomarkers (48).  In terms of 
the AUC, ADAM15 showed higher clinical efficacy (p 
< 0.05) compared to the other candidate genes. The odds 
ratios of ADAM15 and CDC7 also showed statistically-
significant correlations to an OSCC (p < 0.05).
In conclusion, four genes (TNFRSF8, IL12RB2, CDC7 
and ADAM15) were presented as candidates for OSCC 
biomarkers by using a microarray analysis and a qRT-
PCR validation with biostatistical verification. Further 
investigations are needed in order to construct more ac-
curate diagnostic models. To our knowledge, this is the 
first report on OSCC biomarkers in Korean patients.
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